More than 140,000 people from around the world turned to our experts last year for their cancer care. Their trust in MD Anderson pushes us to set the highest standards and to continually improve and strive for excellent patient outcomes.
Late last year, MD Anderson self-reported to the Food and Drug Administration (FDA) an incident involving contaminated platelets that contributed to a patient’s death. Based on the self-reported...
The University of Texas MD Anderson Cancer Center today named Darrow Zeidenstein, Ph.D., as chief development officer. With more than 25 years...
The University of Texas MD Anderson Cancer Center has cooperated fully in two surveys conducted by the Centers for Medicare and Medicaid Services...
A common genetic deficiency empowers glioblastoma to broadcast a molecular message to the wrong type of immune cell, summoning macrophages that protect and nurture the brain tumor instead of attacking it, researchers at The University of Texas MD Anderson Cancer Center report in Cancer Cell.
The team’s work in mouse models of glioblastoma that lack functional cancer-suppressor gene PTEN points to new potential targets for treating...
